Robustness of the Exact t Method for a Three-arm Clinical Endpoint Bioequivalence Study under Non-normality

A clinical endpoint bioequivalence (BE) study seeks to determine the BE of a generic drug (TEST) and an innovator drug (REF). A placebo (PLB) is usually included to demonstrate the study's sensitivity. BE is established if TEST is shown to

Read More